Although humans have been transplanting hearts for 50 years, a heart transplant is still an incredibly complicated procedure posing some major challenges – the available supply of transplantable hearts, getting a recipient’s body to accept another human being’s heart, and having world-class medical facilities and personnel to execute the procedure.
The heart is one of, if not the most important organ in the human body, and humans can’t live without them. With that said, they can’t come from living donors, so available supply is controlled primarily by death. To put it simply, human hearts viable for transplant are very difficult to come across. As we’ve outlined, the waiting list for transplants outgrows the supply further and further every year, so providing hearts for people in need of them only becomes more challenging.
Because of the limited supply of transplantable hearts, it’s important that each transplant procedure is done carefully and correctly so as to make it count, and not waste a valuable human heart. In order for this to happen, each recipient’s body must allow the organ to do its job. However, our bodies can sometimes be overprotective and reject transplanted hearts as foreign objects. This is why it’s absolutely critical to transplant hearts that match recipients’ cells as closely as possible. On top of allowing the new heart to function properly, this can also speed up the post-surgery recovery time.
While one will want their recovery to be as quick as possible, hopefully it will take place in a world-class medical facility with world-class personnel. Since a heart transplant is such a delicate procedure, the environment in which it’s done and the professionals it’s done by play major roles. That need for elite surroundings is why BIOLIFE4D has established operations in the medical and cardiac hubs of Chicago and Houston.
All told, BIOLIFE4D is working to drastically improve the human heart transplant process in one swoop by 3D bioprinting a human heart viable for transplant from a patient’s own cells, and using world-class medical facilities and personnel to do so. There’s one more thing we’ll need, however, and that’s investors like you.